{"id":1017829,"date":"2026-11-05T11:55:30","date_gmt":"2026-11-05T16:55:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/"},"modified":"2026-11-05T11:55:30","modified_gmt":"2026-11-05T16:55:30","slug":"vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/","title":{"rendered":"Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting<sup>\u00ae <\/sup>2026 and Host Investor Conference Call<\/b><\/p>\n<p><i>&#8211; Conference call to discuss topline ECLIPSE 1 results and expanded Phase 2 SOLSTICE data scheduled for November 9, 2026, at 8:30 a.m. ET \/ 5:30 a.m. PT<\/i><\/p>\n<p>SAN FRANCISCO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nVir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the pivotal Phase 3 ECLIPSE 1 trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta in a late-breaking oral presentation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting<sup>\u00ae<\/sup> 2026 in Denver, CO, November 5-9, 2026.<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Primary endpoint results of ECLIPSE 1: A randomized open-label Phase 3 study evaluating efficacy and safety of elebsiran and tobevibart for chronic hepatitis delta<br \/>\n<br \/><\/b>Format: Oral presentation<br \/>\n<br \/>Session: Late Breaking Abstract Parallel Session 1<br \/>\n<br \/>Presenter: Nancy Reau<br \/>\n<br \/>Date: November 8, 2026<br \/>\n<br \/>Time: 2:15 p.m. to 2:30 p.m. MT<\/p>\n<\/li>\n<\/ul>\n<p>\nIn addition to the ECLIPSE 1 late-breaking oral presentation, the Company will present two previously announced oral presentations featuring expanded Phase 2 SOLSTICE data.<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Efficacy of elebsiran (VIR-2218) and tobevibart (VIR-3434) in participants with chronic hepatitis delta infection: Patterns of HDV RNA responses through Week 96<br \/>\n<br \/><\/b>Format: Oral presentation<br \/>\n<br \/>Session: Hepatitis \u2013 Other Infections<br \/>\n<br \/>Presenter: Tarik Asselah<br \/>\n<br \/>Date: November 8, 2026<br \/>\n<br \/>Time: 2:45 p.m. to 3:00 p.m. MT<\/p>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>From inflammation to surveillance: Intrahepatic NK cell remodelling with elebsiran and tobevibart in chronic hepatitis D &#8211; A translational sub-study of the SOLSTICE trial<br \/>\n<\/b><br \/>Format: Oral presentation<br \/>\n<br \/>Session: Inflammation and Immunobiology<br \/>\n<br \/>Presenter: Upkar Gill<br \/>\n<br \/>Date: November 7, 2026<br \/>\n<br \/>Time: 5:45 p.m. to 6:00 p.m. MT<\/p>\n<\/li>\n<\/ul>\n<p><b>Conference Call<\/b><\/p>\n<p>\nVir Biotechnology will host a conference call to discuss the ECLIPSE 1 topline results and expanded SOLSTICE data at 8:30 a.m. ET \/ 5:30 a.m. PT on Monday, November 9. A live webcast will be available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.vir.bio&amp;esheet=54635424&amp;newsitemid=20261105268667&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestors.vir.bio&amp;index=1&amp;md5=b14a26f94b02c2bb86a356ee635a169d\">https:\/\/investors.vir.bio<\/a> and will be archived for 30 days.<\/p>\n<p><b>About the ECLIPSE Registrational Program<\/b><\/p>\n<p>\nECLIPSE is a registrational program to evaluate the efficacy and safety of the elebsiran and tobevibart regimen in patients with chronic hepatitis delta (CHD). ECLIPSE includes three randomized, controlled trials designed to evaluate the regimen in comparison to deferred treatment or bulevirtide. ECLIPSE 1 (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06903338%3Fterm%3DECLIPSE%2C%2520vir%2520biotechnology%26rank%3D1&amp;esheet=54635424&amp;newsitemid=20261105268667&amp;lan=en-US&amp;anchor=NCT06903338&amp;index=2&amp;md5=ae58906455b768ef5a32d2051d217be7\">NCT06903338<\/a>) evaluates the efficacy and safety of the regimen compared to deferred treatment in the U.S. or other regions where bulevirtide use is limited. ECLIPSE 2 (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07128550%3Fterm%3DECLIPSE%2C%2520vir%2520biotechnology%26rank%3D2&amp;esheet=54635424&amp;newsitemid=20261105268667&amp;lan=en-US&amp;anchor=NCT07128550&amp;index=3&amp;md5=dcb7614e9c61e8df4b16d630c3218ddd\">NCT07128550<\/a>) evaluates the efficacy and safety of switching to the regimen in people with CHD who have not achieved viral suppression with bulevirtide therapy. ECLIPSE 3 (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07142811%3Fterm%3DECLIPSE%2C%2520vir%2520biotechnology%26rank%3D1&amp;esheet=54635424&amp;newsitemid=20261105268667&amp;lan=en-US&amp;anchor=NCT07142811&amp;index=4&amp;md5=98e004fef2f404ddb92039c6b7c403f0\">NCT07142811<\/a>) evaluates the regimen compared to bulevirtide in bulevirtide-na\u00efve patients, and it is designed to provide important data to help establish access and reimbursement in key markets. ECLIPSE 1, 2 and 3 are pivotal trials designed to generate a comprehensive data package in support of potential submission to global regulatory agencies.<\/p>\n<p><b>About Elebsiran and Tobevibart<\/b><\/p>\n<p>\nElebsiran and tobevibart are investigational agents being evaluated as a novel combination regimen administered monthly as two separate sequential subcutaneous injections for the treatment of chronic hepatitis delta (CHD). The combination is designed to disrupt the hepatitis delta virus (HDV) life cycle at multiple points by addressing both viral entry and the sustained presence of hepatitis B surface antigen (HBsAg) that enables ongoing HDV replication.<\/p>\n<p>\nElebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) licensed from Alnylam Pharmaceuticals, Inc. It is designed to degrade hepatitis B virus RNA transcripts and limit the production of HBsAg.<\/p>\n<p>\nTobevibart is an investigational broadly neutralizing monoclonal antibody (mAb) targeting HBsAg. It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart was identified using Vir Biotechnology\u2019s proprietary mAb discovery platform. The Fc domain has been engineered to increase immune engagement and clearance of HBsAg immune complexes and incorporates Xencor\u2019s Xtend\u2122 technology to extend half-life.<\/p>\n<p><b>About Chronic Hepatitis Delta (CHD)<\/b><\/p>\n<p>\nCHD is the most severe form of chronic viral hepatitis<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niddk.nih.gov%2Fhealth-information%2Fliver-disease%2Fviral-hepatitis%2Fhepatitis-d%23common&amp;esheet=54635424&amp;newsitemid=20261105268667&amp;lan=en-US&amp;anchor=1&amp;index=5&amp;md5=577f5ffb6654678a049ecc49eddd94b8\"><sup>1<\/sup><\/a> and was recently classified as carcinogenic by the International Agency for Research on Cancer.<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanonc%2Farticle%2FPIIS1470-2045%252825%252900403-6%2Fabstract&amp;esheet=54635424&amp;newsitemid=20261105268667&amp;lan=en-US&amp;anchor=2&amp;index=6&amp;md5=338ff649da14a46e5887fe8c64755bb3\"><sup>2<\/sup><\/a> People living with the disease rapidly progress to cirrhosis, liver failure<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Farchive.cdc.gov%2Fwww_cdc_gov%2Fhepatitis%2Fhdv%2Fhdvfaq.htm%23%3A%7E%3Atext%3DOf%2520people%2520with%2520chronic%2520HDV%2Cis%252040%2520years%2520%252811%2529.&amp;esheet=54635424&amp;newsitemid=20261105268667&amp;lan=en-US&amp;anchor=3&amp;index=7&amp;md5=86e1d373a837effee84adcfeb5119e2d\"><sup>3<\/sup><\/a> and liver-related death.<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niddk.nih.gov%2Fhealth-information%2Fliver-disease%2Fviral-hepatitis%2Fhepatitis-d%23common&amp;esheet=54635424&amp;newsitemid=20261105268667&amp;lan=en-US&amp;anchor=1&amp;index=8&amp;md5=0e3d89efd0a8c3f8c2b0ebef7f0d25ba\"><sup>1<\/sup><\/a> Because ongoing hepatitis delta virus (HDV) replication drives disease progression, achieving undetectable virus, as defined by HDV RNA TND (target not detected), is considered an important virologic marker associated with improved clinical outcomes in CHD.<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fjournals.lww.com%2Fhep%2Ffulltext%2F10.1097%2Fhep.0000000000000642%7Eassociation-of-hepatitis-delta-virus-with-liver-morbidity&amp;esheet=54635424&amp;newsitemid=20261105268667&amp;lan=en-US&amp;anchor=4&amp;index=9&amp;md5=578d9eb9d53b4e039c93acc68ab85aad\"><sup>4<\/sup><\/a> Individuals with CHD who have detectable HDV RNA are at a higher risk of experiencing any liver-related event, including developing compensated and decompensated cirrhosis, hepatocellular carcinoma, liver transplantation and mortality, compared to patients with undetectable HDV RNA.<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fjournals.lww.com%2Fhep%2Ffulltext%2F10.1097%2Fhep.0000000000000642%7Eassociation-of-hepatitis-delta-virus-with-liver-morbidity&amp;esheet=54635424&amp;newsitemid=20261105268667&amp;lan=en-US&amp;anchor=4&amp;index=10&amp;md5=87b0ac61b243cba585924a1b642aa4ba\"><sup>4<\/sup><\/a> There are currently limited approved treatments in the U.S. and globally.<\/p>\n<p><b>About Vir Biotechnology, Inc.<\/b><\/p>\n<p>\nVir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN<sup>\u00ae<\/sup> dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.<\/p>\n<p>\nVir Biotechnology has exclusive rights to the universal PRO-XTEN<sup>\u00ae<\/sup> masking platform for oncology and infectious disease. PRO-XTEN<sup>\u00ae<\/sup> is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105268667r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261105268667\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261105268667\/en\/<\/a><\/span><\/p>\n<p><b>Media Contact<br \/>\n<\/b><br \/>Caren Scannell<br \/>\n<br \/>Director, Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:cscannell@vir.bio\">cscannell@vir.bio<\/a><\/p>\n<p><b>Investor Contact<br \/>\n<\/b><br \/>Kiki Patel, PharmD<br \/>\n<br \/>Head of Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:kpatel@vir.bio\">kpatel@vir.bio<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California Colorado United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Pharmaceutical Oncology Health Infectious Diseases Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261105268667\/en\/2346430\/3\/Vir_Biotechnology_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call &#8211; Conference call to discuss topline ECLIPSE 1 results and expanded Phase 2 SOLSTICE data scheduled for November 9, 2026, at 8:30 a.m. ET \/ 5:30 a.m. PT SAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211; Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the pivotal Phase 3 ECLIPSE 1 trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta in a late-breaking oral presentation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting\u00ae 2026 in Denver, CO, November 5-9, 2026. Primary endpoint &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1017829","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call &#8211; Conference call to discuss topline ECLIPSE 1 results and expanded Phase 2 SOLSTICE data scheduled for November 9, 2026, at 8:30 a.m. ET \/ 5:30 a.m. PT SAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211; Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the pivotal Phase 3 ECLIPSE 1 trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta in a late-breaking oral presentation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting\u00ae 2026 in Denver, CO, November 5-9, 2026. Primary endpoint &hellip; Continue reading &quot;Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-05T16:55:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105268667r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call\",\"datePublished\":\"2026-11-05T16:55:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\\\/\"},\"wordCount\":949,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105268667r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\\\/\",\"name\":\"Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105268667r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-05T16:55:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105268667r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105268667r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/","og_locale":"en_US","og_type":"article","og_title":"Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call - Market Newsdesk","og_description":"Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call &#8211; Conference call to discuss topline ECLIPSE 1 results and expanded Phase 2 SOLSTICE data scheduled for November 9, 2026, at 8:30 a.m. ET \/ 5:30 a.m. PT SAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211; Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the pivotal Phase 3 ECLIPSE 1 trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta in a late-breaking oral presentation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting\u00ae 2026 in Denver, CO, November 5-9, 2026. Primary endpoint &hellip; Continue reading \"Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-05T16:55:30+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105268667r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call","datePublished":"2026-11-05T16:55:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/"},"wordCount":949,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105268667r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/","name":"Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105268667r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-05T16:55:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105268667r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105268667r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-present-topline-phase-3-eclipse-1-data-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta-at-aaslds-the-liver-meeting-2026-and-host-investor-conference-call\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD\u2019s The Liver Meeting\u00ae 2026 and Host Investor Conference Call"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1017829"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017829\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1017829"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1017829"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1017829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}